Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic adenocarcinoma of the breast~* Strong overexpression of HER-2 by immunohistochemistry (3+)~  * 0-2+ tumors allowed if demonstrate amplification by FISH~* Bidimensionally measurable disease~* Brain metastasis must not represent sole site of disease~* No untreated brain metastasis receiving radiotherapy~* Previously treated brain metastases in continued response to radiotherapy and/or surgery for at least 2 months allowed~* Hormone receptor status:~  * Positive or negative~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* ECOG 0-2~Life expectancy:~* At least 3 months~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* AST no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver metastases present)~Renal:~* Creatinine no greater than 1.5 times ULN~Cardiovascular:~* No myocardial infarction within the past 6 months~* No congestive heart failure or unstable angina~* No clinically significant pericardial effusion or arrhythmia~Other:~* No other invasive malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No active uncontrolled infection~* No prior allergic reaction to Cremophor EL, anesthetics, or muscle relaxants~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent filgrastim (G-CSF)~Chemotherapy:~* Prior adjuvant chemotherapy allowed~* Prior taxane therapy allowed~* No prior cisplatin or carboplatin~* No prior chemotherapy for metastatic disease~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~* No prior radiotherapy to more than 25% of marrow~* At least 4 weeks since prior radiotherapy~* No concurrent radiotherapy~Surgery:~* See Disease Characteristics~* At least 4 weeks since prior surgery and recovered~Other:~* At least 7 days since prior parenteral antibiotics

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Schedule A: paclitaxel + carboplatin + trastuzumab (Type: EXPERIMENTAL): Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes and then trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter.
- Schedule B: paclitaxel + carboplatin + trastuzumab (Type: EXPERIMENTAL): Patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 15 minutes on day 1 of weeks 1-3 and trastuzumab IV over 90 minutes immediately after carboplatin on day 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete